X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8) 8
humans (7) 7
animals (5) 5
cell line, tumor (5) 5
mice (5) 5
protein kinase inhibitors - pharmacology (5) 5
cancer (4) 4
cell biology (4) 4
cell proliferation - drug effects (4) 4
melanoma (4) 4
proto-oncogene proteins b-raf - metabolism (4) 4
tumors (4) 4
xenograft model antitumor assays (4) 4
antineoplastic agents - pharmacology (3) 3
biochemical research methods (3) 3
colon-cancer (3) 3
drug resistance, neoplasm - drug effects (3) 3
drug synergism (3) 3
indoles - pharmacology (3) 3
kinases (3) 3
melanoma - drug therapy (3) 3
mutation (3) 3
mutations (3) 3
phosphorylation (3) 3
protein tyrosine phosphatase, non-receptor type 11 - metabolism (3) 3
proto-oncogene proteins b-raf - antagonists & inhibitors (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
receptor, epidermal growth factor - metabolism (3) 3
sulfonamides - pharmacology (3) 3
therapy (3) 3
acquired-resistance (2) 2
analysis (2) 2
antineoplastic agents - therapeutic use (2) 2
biochemistry & molecular biology (2) 2
biochemistry, genetics and molecular biology (2) 2
biology (2) 2
biotechnology & applied microbiology (2) 2
braf inhibition (2) 2
cellular senescence - drug effects (2) 2
colonic neoplasms - drug therapy (2) 2
colonic neoplasms - genetics (2) 2
colonic neoplasms - pathology (2) 2
colorectal neoplasms - genetics (2) 2
colorectal neoplasms - pathology (2) 2
drug resistance (2) 2
drug resistance, neoplasm - genetics (2) 2
expression (2) 2
female (2) 2
gene expression regulation, neoplastic - drug effects (2) 2
genetic aspects (2) 2
inhibition (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - genetics (2) 2
lung neoplasms - pathology (2) 2
map kinase signaling system (2) 2
mathematical & computational biology (2) 2
melanoma - genetics (2) 2
melanoma - metabolism (2) 2
melanoma - pathology (2) 2
mitogen-activated protein kinase kinases - antagonists & inhibitors (2) 2
mitogen-activated protein kinase kinases - metabolism (2) 2
multidisciplinary sciences (2) 2
mutation - genetics (2) 2
pathway (2) 2
proteins (2) 2
ras proteins - genetics (2) 2
ras proteins - metabolism (2) 2
receptor, epidermal growth factor - antagonists & inhibitors (2) 2
receptor, epidermal growth factor - genetics (2) 2
resistance (2) 2
rna, small interfering - genetics (2) 2
vemurafenib (2) 2
activation (1) 1
anaplastic lymphoma kinase (1) 1
antibodies (1) 1
antibodies, monoclonal - pharmacology (1) 1
antibodies, monoclonal, humanized (1) 1
antineoplastic agents - administration & dosage (1) 1
apoptosis - drug effects (1) 1
apoptosis - genetics (1) 1
article (1) 1
bad (1) 1
biological activity (1) 1
biopsy (1) 1
braf (1) 1
braf inhibitor (1) 1
braf mutations (1) 1
breast-cancer (1) 1
c-jun (1) 1
c-myc (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - genetics (1) 1
carcinoma, non-small-cell lung - pathology (1) 1
care and treatment (1) 1
catalysis (1) 1
cell culture (1) 1
cell cycle - drug effects (1) 1
cell lines (1) 1
cell lung-cancer (1) 1
cells (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 03/2012, Volume 483, Issue 7387, pp. 100 - 104
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma(1). However, colon... 
PANITUMUMAB | TARGET | CETUXIMAB | MELANOMA | BRAF MUTATIONS | MULTIDISCIPLINARY SCIENCES | PAPILLARY THYROID-CARCINOMA | KRAS | METASTATIC COLORECTAL-CANCER | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - agonists | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Colorectal Neoplasms - drug therapy | HEK293 Cells | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Colorectal Neoplasms - enzymology | Antibodies, Monoclonal - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Feedback, Physiological - drug effects | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Proteins | Library collections | Studies | Phosphorylation | Kinases | Tumors | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 508, Issue 1, pp. 118 - 122
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably(1,2).... 
GROWTH-FACTOR RECEPTOR | BRAF INHIBITOR | RAF INHIBITION | CELLS | MULTIDISCIPLINARY SCIENCES | IMPROVED SURVIVAL | DIFFERENTIATION | C-JUN | CANCER | EXPRESSION | EGFR | Receptor, Epidermal Growth Factor - genetics | Humans | Receptor Protein-Tyrosine Kinases - biosynthesis | Cellular Senescence - drug effects | Melanoma - enzymology | Antineoplastic Agents - administration & dosage | Receptor, Platelet-Derived Growth Factor beta - genetics | Indoles - administration & dosage | Mitogen-Activated Protein Kinase Kinases - metabolism | Receptor, Epidermal Growth Factor - metabolism | Flow Cytometry | Melanoma - genetics | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | SOXE Transcription Factors - deficiency | Proto-Oncogene Proteins B-raf - metabolism | Receptor, Platelet-Derived Growth Factor beta - metabolism | Receptor, Epidermal Growth Factor - biosynthesis | Gene Library | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Transforming Growth Factor beta - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Transforming Growth Factor beta - metabolism | Receptor, Platelet-Derived Growth Factor beta - biosynthesis | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | SOXE Transcription Factors - genetics | Proteins | Biopsy | Rodents | Genes | Melanoma | Mutation | Kinases | Drug resistance | Patients | Tumors | Index Medicus
Journal Article
Cell Reports, ISSN 2211-1247, 10/2014, Volume 7, Issue 1, pp. 86 - 93
Journal Article
NATURE MEDICINE, ISSN 1078-8956, 07/2018, Volume 24, Issue 7, pp. 961 - 961
RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-small-cell lung cancers (NSCLCs)(1-3). Inhibition of the RAS... 
MEDICINE, RESEARCH & EXPERIMENTAL | TYROSINE PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | MEK INHIBITORS | INDUCED SENESCENCE | CELL BIOLOGY | THERAPY | K-RAS | RESISTANCE | MUTATIONS | EXPRESSION | PROGRESSION | PHOSPHOTYROSINE PHOSPHATASE | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Cellular Senescence - drug effects | Lung Neoplasms - pathology | Guanosine Triphosphate - metabolism | Mutation - genetics | Xenograft Model Antitumor Assays | Mitogen-Activated Protein Kinase Kinases - metabolism | Animals | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Proto-Oncogene Proteins p21(ras) - metabolism | Tyrosine | Ras genes | Genetic aspects | Epidermal growth factor | Lung cancer, Non-small cell | Analysis | Cell culture | Senescence | Lung cancer | Extracellular signal-regulated kinase | Antibodies | Raf protein | Signaling | Immunotherapy | Pancreatic cancer | Protein-tyrosine kinase receptors | Colon | Inhibition | Mutation | Pancreas | Growth factors | Protein-tyrosine kinase | Cancer | Tumors | Index Medicus
Journal Article
Cell Reports, ISSN 2211-1247, 09/2015, Volume 12, Issue 12, pp. 1978 - 1985
Most ( ) mutant melanomas are sensitive to selective BRAF inhibitors, but mutant colon cancers are intrinsically resistant to these drugs because of feedback... 
COLON-CANCER | SHP2 PTPN11 | LUNG-CANCER | MEK INHIBITION | BRAF(V600E) INHIBITION | GROWTH | PROTEIN-TYROSINE PHOSPHATASES | RAF INHIBITORS | MUTATIONS | NOONAN-SYNDROME | CELL BIOLOGY | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - metabolism | RNA, Small Interfering - genetics | Receptor, Epidermal Growth Factor - genetics | ras Proteins - genetics | Colonic Neoplasms - genetics | Colonic Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Genomic Library | ras Proteins - metabolism | Colonic Neoplasms - metabolism | MAP Kinase Signaling System | Receptor, Epidermal Growth Factor - metabolism | Melanoma - genetics | Indoles - pharmacology | Lentivirus - genetics | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Transduction, Genetic | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - antagonists & inhibitors | Melanoma - pathology | Sulfonamides - pharmacology | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Melanoma - drug therapy | Cell Line, Tumor | Mice, Inbred NOD | High-Throughput Nucleotide Sequencing | Mice | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics | Genetic Vectors | Drug Resistance, Neoplasm - drug effects | RNA, Small Interfering - metabolism | Index Medicus
Journal Article
Bioinformatics, ISSN 1367-4803, 12/2018, Volume 34, Issue 23, pp. 4079 - 4086
Abstract Motivation Intracellular signalling is realized by complex signalling networks, which are almost impossible to understand without network models,... 
ACTIVATION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | CANCER | BIOCHEMICAL RESEARCH METHODS | MATHEMATICAL & COMPUTATIONAL BIOLOGY | ERK
Journal Article
Bioinformatics, ISSN 1367-4803, 09/2018, Volume 34, Issue 17, pp. i997 - i1004
Abstract Motivation Signal-transduction networks are often aberrated in cancer cells, and new anti-cancer drugs that specifically target oncogenes involved in... 
COLON-CANCER | BRAF(V600E) INHIBITION | PREDICT | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | BIOCHEMICAL RESEARCH METHODS | MATHEMATICAL & COMPUTATIONAL BIOLOGY | ACQUIRED-RESISTANCE | Eccb 2018 | European Conference on Computational Biology Proceedings
Journal Article
Cancer Research, ISSN 0008-5472, 10/2014, Volume 74, Issue 19 Supplement, pp. 3697 - 3697
Journal Article
Molecular and Cellular Proteomics, ISSN 1535-9476, 10/2018, Volume 17, Issue 10, pp. 1892 - 1908
Journal Article
11/2015
The current disclosure relates to the use of pharmaceuticals and pharmaceutical combinations and compositions useful in the treatment of certain types of... 
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS | HYGIENE | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | MEDICAL OR VETERINARY SCIENCE | HUMAN NECESSITIES
Patent
Current Opinion in Genetics & Development, ISSN 0959-437X, 02/2019, Volume 54, pp. 48 - 54
Acquired resistance is a major limitation for the successful treatment of cancer patients. Although numerous efficacious cancer therapeutics have been... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.